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Andreas Schneeweis5 and Fritz Jänicke1Abstract
Background: In this study, we examined patients who had non-progressive disease for at least 2 years after diagnosis
of inoperable locoregional recurrent or metastatic breast cancer under continuous trastuzumab treatment. Our primary
goal was to assess the long-term outcome of patients with durable response to trastuzumab.
Methods: 268 patients with HER2-positive inoperable locally recurrent or metastatic breast cancer and non-progressive
disease for at least 2 years under trastuzumab treatment were documented retrospectively or prospectively in the
HER-OS registry, an online documentation tool, between December 2006 and September 2010 by 71 German oncology
centers. The study end point was time to tumor progression.
Results: Overall, 47.1% of patients (95% confidence interval (CI): 39.9–54.1%) remained in remission for more than
5 years, while the median time to progression was 4.5 years (95% CI: 4.0–6.6 years). Lower age (<50 years) and good
performance status (ECOG 0) at time of trastuzumab treatment initiation as well as complete remission after initial
trastuzumab treatment were associated with longer time to progression. Interruption of trastuzumab therapy correlated
with shorter time to progression.
Conclusions: HER2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a
long-term tumor remission of several years.
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Although the majority of breast cancer patients can be
cured of their disease, up to 20% will develop metastatic
breast cancer (MBC). The Human Epidermal Growth Fac-
tor Receptor 2 (HER2) is overexpressed or amplified in
15% of breast tumors [1] and is associated with a more ag-
gressive tumor behavior, shorter disease-free and overall
survival [2-4]. Trastuzumab (Herceptin®), a monoclonal
antibody directed against HER2, has shown to improve
survival in combination with chemotherapy compared to
non-trastuzumab-based treatment [5-7]. It has therefore
become the standard treatment in adjuvant and metastatic
HER2-positive breast cancer. Although the majority of* Correspondence: iwitzel@uke.de
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unless otherwise stated.patients with MBC treated with trastuzumab-based regi-
mens progress within one year [5,8], few patients experi-
ence prolonged remission [9,10]. Limited data have been
published on long term remission under treatment with
trastuzumab and are usually based on case reports or
small patient numbers [11-13]. Aspects such as clinical
predictive factors of long-term response to trastuzumab or
the optimal duration of trastuzumab therapy in MBC pa-
tients achieving stable response remain to be reported.
The primary goal of this study was to assess the long-term
outcome of patients with durable response to trastuzu-
mab. In addition, factors that could be associated with
long-term tumor remission under trastuzumab were iden-
tified in an exploratory analysis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Selection of patients
Patients with HER2 positive inoperable locally recurrent
or metastatic breast cancer and non-progressive disease
for at least 2 years under continuous trastuzumab ther-
apy (complete or partial response or stable disease) met
the inclusion criteria to be documented in the HER-OS
database. Positive HER2 status was defined as immunohis-
tochemistry (IHC) staining of 3+ or immunohistochemis-
try staining of 2+ and positive fluorescence in-situ
hybridization (FISH, HER2/CEP17 ratio >2.2). Between
December 2006 and September 2010, 447 patients under
trastuzumab treatment were documented in 71 German
medical centers within the HER-OS database, an online-
documentation platform for patients with advanced HER2
positive breast cancer. The database for the register was
set up by an review board (see Authors’ contributions) as a
collection of case reports. The project fulfilled the criteria
of a non-interventional study according to the European
Community and German legislation, and therefore required
no ethical committee vote [14]. Patients gave informed con-
sent to have their medical records reviewed according to the
review board guidelines. The not publicly available HER-OS
database (owner: Roche Pharma AG, Germany) included
documentation of demographic data, clinico-pathological
data of the primary tumor, treatment strategies and con-
comitant diseases. Treatment with trastuzumab, further an-
tineoplastic therapies and tumor status were documented
every 6 months after treatment initiation with trastuzumab.
Retrospective as well as partial retro-/prospective documen-
tation was allowed. Patient data was anonymized.
The study end point was time to tumor progression
(TTP). The HER-OS database was closed in September
2010. The observation period until disease progression
or end of study was 41.2 months (median; range: 24.3–
117.1 months).
Only 268 of 447 patients (60.0%) had complete docu-
mentation of prior treatments, met the inclusion criteria,
were without progression for at least 2 years after the
initiation of trastuzumab treatment, and were therefore
considered eligible for further analyses.
Treatment
Since this study was non-interventional, patients were
treated at their physician’s choice. The physicians chose
trastuzumab treatment intervals and dosages as well as
combination of trastuzumab with other chemotherapeu-
tic or endocrine treatments. The physicians also deter-
mined cardiac monitoring intervals, which were mostly
performed in 6-monthly intervals.
Statistical methods
Statistical analysis focused on the summary and detailed de-
scription of the data. Unless otherwise stated, percentageswere displayed as adjusted values, so that patients with
missing data were not taken into account.
Primary outcome variable of the study was time to
tumor progression (TTP). Nonparametric estimates of
survivor functions were calculated by the Kaplan-Meier
method. Differences in time distributions were analyzed
using Peto’s logrank test. In a multivariate analysis includ-
ing all parameters of the univariate analysis, forward selec-
tion was performed with an entry of 0.25 and a stay of
0.15. Results were regarded as statistically significant at a
p-value ≤0.10. Analyses in subgroups were made post-hoc
and should be seen as exploratory. The statistical analysis
was performed with the program SAS™ version 9.2.
Results
Patients’ characteristics
The median age at diagnosis of breast cancer was
53.8 years (range 29–86 years). 27.2% of patients (n = 64)
had metastases at first diagnosis of breast cancer. 37.5%
of patients (n = 94) were hormone receptor negative. Of
those patients with non-metastatic disease at diagnosis,
76.6% (n = 131) had received chemotherapy in the adju-
vant setting, 42.7% (n = 73) a taxane containing regimen.
50.9% (n = 87) had received adjuvant endocrine treatment,
8.2% (n = 14) adjuvant trastuzumab treatment. The me-
dian disease-free survival for 131 patients with non-
metastatic disease at diagnosis amounted to 3.3 years
(range: 1 month – 15.5 years).
At the time of disease recurrence or onset of meta-
static disease, 15.3% (n = 41) of the 268 women suffered
from inoperable locoregional recurrent disease, 52.2% (n =
140) from distant metastases and 32.5% (n = 87) from both.
Metastases were predominantly found in bone (n = 102;
38.1%), liver (n = 88; 32.8%), and lung (n = 75; 28.0%). Brain
metastases were present in only 2.2% of documented pa-
tients (n = 6).
In general, patients had a good performance status at
the beginning of trastuzumab therapy. 49.8% (n = 115)
had Eastern Cooperative Oncology Group (ECOG) per-
formance status 0. 42.2% (n = 108) of patients had nor-
mal weight, while 51.6% (n = 132) were overweight or
obese, and 6.3% (n = 16) were underweight.
Nearly every fifth patient (19.4%) presented with relevant
comorbidities, which were mostly hypertension (10.1% of
all patients) or cardiac arrhythmia (2.6% of all patients).
Tables 1 and 2 provide detailed patients’ characteristics
at the time of diagnosis of breast cancer and at the start
of palliative trastuzumab treatment.
Trastuzumab treatment
Although the administration of trastuzumab as weekly
and three-weekly infusion was balanced at the beginning
of palliative treatment, the majority of patients switched
to three-weekly intervals during therapy (84.0%).
Table 1 Patient characteristics at diagnosis of breast cancer
Characteristics Number %
Age, years














+2 and positive FISH 11 4.1
+3 257 95.9
Estrogen receptor (ER)/progesterone receptor (PR)
ER positive/PR positive 105 41.8
ER positive/PR negative 38 15.1
ER negative/PR positive 14 5.6
ER negative/PR negative 94 37.5
ER or PR unknown 17




Median (Range) 58.5 (31–86)
BMI (kg/m2)









Median (Range) 37.3 (1–413)
Site of disease recurrence
Inoperable locoregional recurrence 41 15.3
Metastatic disease 140 52.2
Both 87 32.5
Site of locoregional recurrence
Breast 47 17.5
Axillary lymph nodes 64 23.9
Supraclavicular lymph nodes 33 12.3
Chest wall 23 8.6
not specified 15 5.6
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bination treatment with chemotherapy (n = 169; 63.1%)
or with endocrine treatment (n = 92; 34.3%). The most
commonly used chemotherapeutic agents were taxanes
(40.3% total; 20.9% paclitaxel; 19.4% docetaxel), vinorel-
bine (22.4%) and antimetabolites (17.2% total; 12.7% capecit-
abine; 2.6% gemcitabine; 1.9% fluorouracil). Anthracyclines
were also combined with trastuzumab in 2.6% of
women (2.2% doxorubicin; 0.4% epirubicin). In case of
endocrine therapy in combination with trastuzumab,
patients mostly received an aromatase inhibitor or tam-
oxifen. In 21.6% of women (n = 58), trastuzumab was
used as single agent.
Interruption of trastuzumab therapy
17 patients (6.4%) received lower trastuzumab dosages
due to therapy interruption, mostly due to other illnesses.
The most frequent reasons for interruption of trastuzu-
mab therapy were patient’s wish (1.5%) or cardiac adverse
event (1.1%). Patients who experienced progression within
6 months after trastuzumab interruption (n = 3) were ex-
cluded from further analyses.Response to trastuzumab
A clinical response to trastuzumab treatment was re-
quired in order to be included in the study. 38.7% of pa-
tients (n = 103) had complete remission, 32.0% (n = 85)
partial remission, and 29.3% (n = 78) stable disease as
best response to trastuzumab treatment. A remission
(complete or partial) was documented after a median
time of 7.3 months since treatment initiation.
Until the end of the study, 126 patients (47.0%) had pro-
gressive disease during continuous trastuzumab treatment
with an estimated median time to progression (TTP) of
4.5 years (95% CI: 4.0–6.6 years). It was estimated that
47.1% of patients (95% CI: 39.9–54.1%) remained in remis-
sion for more than 5 years, 40.5% (95% CI: 32.1–48.7%)
for more than 7 years, and 29.2% (95% CI: 15.1–44.8%) for
more than 9 years (Table 3, Figure 1).







95%-confidence interval of survival estimates Patients
leftLower limit Upper limit
1 and 2 0 0 100.0% 268
3 72 29 71.6% 65.6% 76.8% 167
4 29 39 57.1% 50.4% 63.3% 99
5 15 29 47.1% 39.9% 54.1% 55
6 3 22 43.9% 36.2% 51.3% 30
7 2 15 40.5% 32.1% 48.7% 13
8 1 4 36.5% 26.0% 47.0% 8
9 1 3 29.2% 15.1% 44.8% 4
10 3 1 0.0% - - 0
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Patients who were younger (age <50 years) at diagnosis
of inoperable locoregional recurrent or metastatic dis-
ease and had a good performance status (ECOG 0) ex-
hibited a trend towards longer TTP in the univariate
analysis (p = 0.07 and p = 0.08, respectively; Table 4). In
addition, best response to trastuzumab treatment had an
influence on TTP (p = 0.057; Table 4). Interruption of
trastuzumab treatment was associated with shorter TTP
(p = 0.0005; Table 4). We could not observe an influence
of tumor size, grading, hormone receptor status, nodal
status or disease-free survival in univariate analysis. The
absence of distant metastases at the onset of trastuzu-
mab treatment or the initial combination of trastuzumab
with endocrine therapy or chemotherapy had also no
impact on TTP (Table 4).
In the multivariate analyses, interruption of trastuzu-
mab treatment turned out to be associated with shorter
TTP (p = 0.0015; data not shown).
Discussion
In our group of patients responding at least 2 years to tras-
tuzumab treatment for inoperable locoregional recurrent orFigure 1 Probability of progression during palliative
trastuzumab treatment.metastatic breast cancer, long-term tumor remission for
several years could be achieved. The median time to pro-
gression in our study cohort was 4.5 years. We could iden-
tify that younger age (under the age 50) and good
performance status (ECOG 0) at the initiation of trastuzu-
mab treatment were associated with longer TTP. An inter-
ruption of trastuzumab treatment correlated with shorter
TTP in univariate and multivariate analysis.
Trastuzumab therapy has increased response rates and
survival times in the metastatic setting [15]. We can report
a complete remission rate of 38.7% in HER2 positive pa-
tients receiving trastuzumab treatment for advanced
breast cancer. To our knowledge, we are the first to de-
scribe a clinical cohort of patients with advanced breast
cancer disease who benefit from trastuzumab treatment
for several years.
Long-term follow-up, beyond 3 to 5 years, is excep-
tional in the metastatic breast cancer literature as me-
dian survival ranges between 2 and 4 years. While most
patients with metastatic breast cancer respond transi-
ently to conventional treatments, the majority develop
evidence of progressive disease within 12 to 24 months
of first-line therapy [16,17]. However, some patients who
achieve a complete remission after chemotherapy remain
in this state for prolonged periods of time, with some
even beyond 20 years [18,19]. Tomiak et al. reported
that 20% of metastatic breast cancer patients who
achieved complete remission with chemotherapy were
alive and without disease progression for more than
5 years [19]. In another retrospective analysis of 147 pre-
menopausal women with metastatic breast cancer re-
ceiving chemotherapy, 28% of patients were reported to
be alive after a follow-up period of 5 years [20]. In a co-
hort of 1581 metastatic breast cancer patients treated
with anthracycline containing therapy for a maximum of
2 years in the 1970s and 1980s, complete remission rates
of 16.6% were described. 3% of patients remained in
complete remission for more than 5 years [18]. The
long-term survivors described in those studies were
Table 4 Association of clinicopathological and treatment characteristics with time to tumor progression (univariate analysis)
Parameter Patients (total) Patients (progressed) Time to progression (years) p-value
TNM status at diagnosis T0-T1 77 28 5.10 4.13- n.e. 0.1423
T2-T4 176 92 4.06 3.56-7.74
N0 74 37 4.11 3.30-6.05 0.2813
N1-N3 165 75 5.06 4.05-9.76
M0 171 79 5.06 4.05-9.70 0.2367
M1 64 31 4.39 3.51-6.58
Grading G1-G2 132 63 4.13 3.55-6.05 0.3122
G3 118 55 5.06 4.04-9.53
Disease-free survival 0-5 years 203 91 5.12 4.11-8.72 0.2183
>5 years 56 32 3.46 3.00-4.44
Hormone receptor status ER negative 109 48 5.96 4.04-9.53 0.1876
ER positive 148 73 4.13 3.55-6.05
PR negative 132 61 5.06 4.05-6.58 0.6547
PR positive 120 56 4.11 3.53-9.70
ER and PR negative 94 42 5.06 4.04-9.53 0.3789
ER or PR positive 157 75 4.18 3.56-6.58
Age at trastuzumab start < 50 years 70 32 5.96 4.11-9.76 0.0744
≥50 years 198 94 4.20 3.56-6.05
ECOG status at trastuzumab start 0 115 54 4.61 3.91-9.76 0.0812
1-4 116 59 4.05 3.44-5.96




recurrent only 55 22 9.70 3.63-9.70
Bone metastases only 41 21 4.05 3.30-n.e.
Visceral metastases 139 69 4.39 3.55-6.58
Initial response to trastuzumab
treatment
Complete remission 48 16 8.72 4.46-9.76 0.0571
Partial remission 80 46 4.03 3.50-4.41
Stable disease 82 37 4.66 3.56-n.e.
Interruption of trastuzumab
treatment
no therapy interruption 251 109 5.13 4.11-9.53 0.0005
therapy interruption 14 14 3.51 2.36-4.44
Witzel et al. BMC Cancer 2014, 14:806 Page 5 of 7
http://www.biomedcentral.com/1471-2407/14/806usually young, had excellent performance status and lim-
ited metastatic disease. In line with these results, we
were able to show that of all clinicopathological parame-
ters, age at initiation of trastuzumab treatment (under
age 50), good performance status (ECOG 0) and initial
response to trastuzumab treatment (complete remission)
were associated with longer TTP. However, also patients
with only partial or stable disease had long-term tumor
remission. Interestingly, in our group of patients, site of
disease recurrence was not associated with TTP (inoper-
able locoregional disease recurrence vs. bone metastases
vs. visceral metastases).
As our data base was documented in several institutions,
it reflects the reality of medical care of HER2 positive
MBC patients between 2006 and 2010. Most of the pa-
tients had received trastuzumab in combination with
chemotherapy or endocrine therapy while 20% of patientshad received trastuzumab only as monotherapy. Accord-
ing to published data, trastuzumab as single-agent first-
line treatment in MBC showed efficacy. 57% of responding
patients had stable disease longer than 12 months [6]. In
HER2 positive MBC patients who progressed under at
least one cytotoxic regimen, response rates of 48% (19%
complete or partial remission, 29% stable disease) with
trastuzumab monotherapy were reported [21]. In this trial,
one third of patients lived for more than three years with
trastuzumab monotherapy.
We were able to demonstrate that therapy cessation or
interruption should be avoided as it was associated with
shorter TTP in our patient cohort. Continuous suppres-
sion of the HER2 pathway may be important, and was
already demonstrated by the benefit of trastuzumab use
beyond progression [22]. Our data is supported by a retro-
spective cohort of 84 patients treated with trastuzumab
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stopped trastuzumab treatment after two years of re-
sponse, in this institution durable response rates were
lower than in the institution that continued trastuzumab
treatment after two years of response (durable response
rates 6 versus 11%) [10]. Although there might be a benefit
of longer trastuzumab treatment in the metastatic setting,
the duration of trastuzumab treatment is still unclear.
The study was designed to find new hypotheses re-
garding long-term remission. Therefore a significance
level of p < 0.1 seemed appropriate. A lower p-value of
p = 0.05 as used in randomized clinical trials could have
led to the exclusion of hypotheses that might be worth
to evaluate further. A drawback of our study is that it is
a single-arm multicenter study with no comparative co-
hort, so that we were not able to draw unequivocal con-
clusions but could only describe parameters influencing
long-term remission within a highly selected sample. It
is important to note that we report only time to disease
progression and that we have not collected data about
overall survival. However, overall survival rates can be
expected to be significantly longer than the TTP re-
ported here because several anti-HER2 treatment strat-
egies can still be applied in HER2 positive metastatic
breast cancer after disease progression.
Conclusions
Although the fraction of metastatic breast cancer pa-
tients with long-term tumor remission is small, we pro-
vide evidence that HER2 positive patients who initially
respond to palliative treatment with trastuzumab can
achieve a long-term tumor remission of several years.
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